|
|
Volumn 22, Issue 6, 2004, Pages 639-640
|
|
Sanofi takeover jeopardizes Aventis biotech deals
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANEMIC AGENT;
ANTIDEPRESSANT AGENT;
ANTINEOPLASTIC AGENT;
CANNABINOID 1 RECEPTOR;
CANNABINOID RECEPTOR ANTAGONIST;
CICLESONIDE;
CORTICOTROPIN RELEASING FACTOR;
ERLOTINIB;
ERYTHROPOIETIN;
FONDAPARINUX;
IMMUNOMODULATING AGENT;
INFLUENZA VACCINE;
IRINOTECAN;
NADROPARIN;
NICOTINIC AGENT;
OBLIMERSEN;
PRALNACASAN;
RIMONABANT;
SYNTHETIC PEPTIDE;
UNCLASSIFIED DRUG;
ALCOHOLISM;
ALLERGIC RHINITIS;
ANEMIA;
ASTHMA;
BIOTECHNOLOGY;
BLOOD CLOTTING DISORDER;
CANCER;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL;
COLORECTAL CANCER;
DRUG INDUSTRY;
GENE MAPPING;
HUMAN;
LIVER DISEASE;
MELANOMA;
MYELOMA;
NOTE;
OBESITY;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SMOKING CESSATION;
VACCINATION;
ANTITRUST LAWS;
COOPERATIVE BEHAVIOR;
DRUG INDUSTRY;
FRANCE;
HUMANS;
INTERNATIONAL COOPERATION;
RESEARCH;
|
|
EID: 2542587821
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0604-639 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|